Patents by Inventor Young Kee Shin
Young Kee Shin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970732Abstract: The present invention relates to a method for determining the DNA quality of a biological sample and, more specifically, to a method for determining the DNA quality of a biological sample by performing a quantitative polymerase chain reaction (PCR) using primers capable of amplifying a target gene, a method for preparing the primers used in the method, and a method for standardizing the amount of detected target gene mutation by using the determined DNA quality. The method of the present invention enables objective evaluation of the DNA quality of a biological sample used in gene analysis and the presentation of objective results on the expression ratio of a gene mutation, thereby providing reliable information in the fields of clinical research and companion diagnosis.Type: GrantFiled: April 4, 2018Date of Patent: April 30, 2024Assignees: GENCURIX INC., LOGONE BIO CONVERGENCE RESEARCH FOUNDATIONInventors: Young Kee Shin, Jin Ju Kim, Sung Su Kim, Hyun Jeung Choi, Young Ho Moon, Myung Sun Kim, Jee Eun Kim
-
Patent number: 11840733Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.Type: GrantFiled: November 21, 2017Date of Patent: December 12, 2023Assignee: GENCURIX INC.Inventors: Sang Rae Cho, Young Ho Moon, Jin Il Han, Young Kee Shin
-
Publication number: 20230323464Abstract: The present invention relates to a method for predicting the prognosis of abreast cancer patient and, more particularly, to a method for predicting the prognosis of breast cancer by combining immune-related genes. The present invention is applicable to all breast cancer patients regardless of the breast cancer molecular subtype, and in addition, if the immune-related gene combination is used to predict the prognosis of breast cancer, as provided in the present invention, it is possible to predict the prognosis of a breast cancer patient without information on proliferation genes.Type: ApplicationFiled: May 12, 2021Publication date: October 12, 2023Inventors: Young Kee Shin, Hannah Lee
-
Patent number: 11759500Abstract: The present invention provides a PEGylated IFN-? variant and a composition for preventing or treating hyperproliferative diseases, inflammatory diseases, autoimmune diseases or viral infectious diseases, the composition comprising the PEGylated IFN-? variant as an effective ingredient. The PEGylated IFN-? variant of the present invention has an excellent anti-viral efficacy, immune regulatory function and anti-cell growth efficacy by virtue of better pharmacokinetic properties compared to native IFN-? and non-PEGylated IFN-? variants, and therefore can be used usefully against various diseases. The present invention provides good patient convenience in terms of administration due to exhibition of an excellent pharmacological activity effect upon administration and a significant increase of half-life in blood over existing interferon formulations.Type: GrantFiled: July 24, 2015Date of Patent: September 19, 2023Assignee: Abion Inc.Inventors: Young-Kee Shin, Young-Deug Kim, Kyoung Song, Dong Hee Na, Seong Hoon Jeong, Dae Duk Kim, In Soo Yoon, Hee Jung Lee, Sae Hyung Lee
-
Publication number: 20230265172Abstract: The present invention relates to a humanized antibody specific to a Bacillus anthracis protective antigen and a preparation method thereof. An antibody library is created by obtaining a Bacillus anthracis protective antigen antibody of a monkey from immune cells obtained by immunizing a Bacillus anthracis protective antigen, an antibody specific to the Bacillus anthracis protective antigen is selected from the created antibody library, and, on the basis of the antibody, a humanized antibody specific to the Bacillus anthracis protective antigen is finally selected by creating a humanized antibody library against a Bacillus anthracis protective antigen.Type: ApplicationFiled: July 26, 2021Publication date: August 24, 2023Inventors: Chi-Ho Yu, Chang-Hwan Kim, Gyeung-Haeng Hur, Seong-Tae Jeong, Dong-Hyun Song, Hae-Eun Joe, Na-Young Kim, Jun-Young Choi, Young-Kee Shin, Hyun-Ho Jeong, Seung-Chul Jun
-
Publication number: 20230241176Abstract: The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-threonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine.Type: ApplicationFiled: August 29, 2022Publication date: August 3, 2023Inventors: Young Kee SHIN, Tae Eun KIM, Sung Youl HONG, Jun Young CHOI, Na Young KIM
-
Patent number: 11464832Abstract: The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-treonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine, and to a composition for sensitizing interferon beta resistant cancer cells comprising cFLIP siRNA as an active ingredient.Type: GrantFiled: July 31, 2017Date of Patent: October 11, 2022Assignees: SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION, ABION INC.Inventors: Young Kee Shin, Tae Eun Kim, Sung Youl Hong, Jun Young Choi, Na Young Kim
-
Publication number: 20220220208Abstract: The present invention relates to an anti-c-Met agonist antibody and use thereof, and more particularly, to an agonist antibody or fragment thereof that specifically binds to a human-derived c-Met protein, to a method for producing the same, to c-Met specific detection method using this, to a composition for preventing or treating cancer comprising the same, to a composition for inducing stem cell differentiation, and a culture medium for stem cells. The method of the present invention can be usefully used for detecting c-Met antibodies, inducing stem cell differentiation using the antibody, and treating or preventing cancer.Type: ApplicationFiled: December 6, 2019Publication date: July 14, 2022Inventors: Young Kee SHIN, Ji Hye LEE, Young Deug KIM, I, Jun Young CHOI
-
Publication number: 20220220207Abstract: The present invention relates to an anti-c-Met agonist antibody and use thereof, and more particularly, to an agonist antibody or fragment thereof that specifically binds to a human-derived c-Met protein, to a method for producing the same, to c-Met specific detection method using this, to a composition for preventing or treating cancer comprising the same, to a composition for inducing stem cell differentiation, and a culture medium for stem cells. The method of the present invention can be usefully used for detecting c-Met antibodies, inducing stem cell differentiation using the antibody, and treating or preventing cancer.Type: ApplicationFiled: December 6, 2019Publication date: July 14, 2022Inventors: Young Kee SHIN, Ji Hye LEE, Young Deug KIM, I, Jun Young CHOI
-
Patent number: 11286296Abstract: The present invention provides: an antibody which specifically bonds to human NINJ-1; and a fragment thereof. The antibody or the fragment thereof according to the present invention has very high bonding affinity and bonding specificity with respect to a human NINJ-1 or a homogeneous binding site of the protein, and does not exhibit cross-reactivity with NINJ-1 proteins that are derived from other organisms and have high protein similarity. Accordingly, the present invention provides significant advantages with respect to accuracy and sensitivity and the like, not only in diagnosing disease related to NINJ-1 proteins but also in inhibiting pathological conditions involving NINJ-1 proteins. In particular, the antibody provided according to the present invention has a remarkable effect of inhibiting attachment between immunocytes and human cerebral endothelial cells, and thus has an effect of treating multiple sclerosis.Type: GrantFiled: August 28, 2017Date of Patent: March 29, 2022Assignees: ABION INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventors: Young Kee Shin, Seahyung Lee, Kyoung Song, Ji Hye Lee
-
Publication number: 20220089684Abstract: The present invention relates to a type 1 interferon neutralizing FC-fusion protein and a use thereof and, more specifically, to: a dimer-type polypeptide to which a monomer comprising an interferon receptor fragment or an antibody Fc fragment is bound; a preparation method there for; and a pharmaceutical composition comprising same. The type 1 interferon neutralizing FC-fusion protein of the present invention blocks binding between type 1 interferon and an interferon receptor, and has an excellent ability of inhibiting the signaling and biological activities of interferon, thereby enabling diseases mediated by a type 1 interferon to be effectively treated.Type: ApplicationFiled: December 20, 2019Publication date: March 24, 2022Inventors: Young Kee SHIN, Sae Hyung LEE, Sung Su KIM
-
Patent number: 11261482Abstract: The present invention relates to a composition for detecting an epidermal cell growth factor receptor gene mutation and to a kit comprising the composition and, more specifically, to a primer and probe set composition for detecting an epidermal cell growth factor gene mutation, and to a kit for detecting an EGFR gene mutation, comprising the composition. A method according to the present invention can not only predict and diagnose responsiveness to a therapeutic agent for the prognosis of a cancer patient, but also predict a cancer metastasis or relapse Thus, the method can be useful for the purposes of determining the need to administer an anticancer therapeutic agent and guiding the direction of future treatment, and for monitoring a cancer metastasis or relapse.Type: GrantFiled: May 25, 2017Date of Patent: March 1, 2022Assignee: GENCURIX INCInventors: Young Kee Shin, Bohyun Byun, Hyunjeung Choi, Joon Seok Choi, Young Ho Moon, Jong Heun Lee, Sang Rea Cho, Jee Eun Kim, Myungsun Kim
-
Patent number: 11220716Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy. Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.Type: GrantFiled: March 28, 2018Date of Patent: January 11, 2022Assignee: GENCURIX INC.Inventors: Sang Rae Cho, Young Ho Moon, Jin Il Han, Young Kee Shin
-
Publication number: 20210299225Abstract: The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-treonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27th arginine amino acid with threonine or serine, and to a composition for sensitizing interferon beta resistant cancer cells comprising cFLIP siRNA as an active ingredient.Type: ApplicationFiled: July 31, 2017Publication date: September 30, 2021Inventors: Young Kee SHIN, Tae Eun KIM, Sung Youl HONG, Kyoung SONG, Hun Soon JUNG, Joo Seok KIM, Sang Yun LEE
-
Patent number: 11107552Abstract: Disclosed are data processing and analysis methods for gene expression data for identifying endogenous reference genes and a composition for the quantitative analysis of gene expression, comprising a pair of primers and/or probes useful in amplifying the identified endogenous reference genes. Introduced with the concepts of “Zero's proportion” and CV, the method allows different datasets to be integrally analyzed, thereby searching for novel reference genes. By the method, 2,087 genes are first found as housekeeping genes which are expressed in most tissues, and the usefulness thereof in the relative quantification of different target genes is determined by analyzing their expression stability. Of the 2,087 genes, 13 genes show higher expression stability with lower expression levels across a wide range of samples than traditional reference genes such as GAPDH and ACTS, and therefore are suitable for the normalization of universal genes having relatively low expression levels.Type: GrantFiled: September 12, 2018Date of Patent: August 31, 2021Assignees: ABION, INC., GENCURIX INC.Inventors: Young Kee Shin, Mi Jeong Kwon, En Sel Oh, Yong Ho In, Sang Seok Koh
-
Publication number: 20210115134Abstract: The invention of the present application relates to a use of an antibody biding specifically to ECL-2 of claudin 3 and functional fragments thereof in cancer cell detection, diagnosis, imaging, and application to cancer treatment (anticancer use of the antibody itself, and application to ADC and CAR-expression cells (particularly immune cells)), an antibody that includes a characteristic CDR sequence exerting a remarkable effect in such uses, and a functional fragment thereof.Type: ApplicationFiled: March 27, 2019Publication date: April 22, 2021Inventors: Young Kee SHIN, Sung Youl HONG, Young Deug KIM, Jun Young CHOI, Heo Bin YANG, Ha Yeon PARK, Sung Su KIM
-
Publication number: 20210009720Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same.Type: ApplicationFiled: September 16, 2020Publication date: January 14, 2021Inventors: Young Kee SHIN, Young Deug KIM, Jun Young CHOI, Tae Eun KIM, Young Jin LEE, Ju Ho LEE, Yeong Mun KIM
-
Patent number: 10806799Abstract: The present invention relates to an immunocytokine in which a human interferon-beta variant is conjugated to an antibody or a fragment thereof, and a method for preparing the same. The human interferon-beta variant has superior activity or functions compared with natural interferon-beta, and the productivity of the immunocytokine according to the present invention is excellent. In addition, the immunocytokine according to the present invention can be favorably used as a target therapeutic agent for multiple sclerosis or cancer since the immunocytokine express both of functions of the interferon-beta and characteristics of the antibody binding to a specific antigen.Type: GrantFiled: August 31, 2017Date of Patent: October 20, 2020Assignee: GENOPHARM INC.Inventors: Young Kee Shin, Young Deug Kim, Jun Young Choi, Tae Eun Kim, Young Jin Lee, Ju Ho Lee, Yeong Mun Kim
-
Patent number: 10718030Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy. Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient, and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.Type: GrantFiled: March 28, 2018Date of Patent: July 21, 2020Assignee: GENCURIX INC.Inventors: Sang Rae Cho, Young Ho Moon, Jin Il Han, Young Kee Shin
-
Patent number: 10655187Abstract: The present invention relates to a gene for predicting or diagnosing the prognosis of early-stage breast cancer and to a use thereof, and more specifically relates to a genetic marker for predicting or diagnosing the prognosis of breast cancer, including TRBC1 (T cell receptor beta constant 1), BTN3A2 (butyrophilin, subfamily 3, member A2) or HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) for providing information necessary for predicting or diagnosing the prognosis of a breast cancer patient. The genetic marker of the present invention allows the prediction or diagnosis of the prognosis of a breast cancer patient, and can therefore advantageously be used for the purpose of providing a direction as to the future course of breast cancer treatment, including a decision on whether anticancer therapy is necessary.Type: GrantFiled: October 9, 2018Date of Patent: May 19, 2020Assignee: GENCURIX INC.Inventors: Young Kee Shin, Young-Deug Kim, En Sel Oh, Jun Young Choi, Sang Rea Cho